The information on this website is not intended for diagnosis or treatment. Please consult your physician for health concerns.

+90 850 321 50 00

CMV Reactivation After Hematopoietic Cell Transplantation (HCT)

Cytomegalovirus reactivation in adult allogeneic hematopoietic cell transplant recipients, occurring during prolonged T-cell immunodeficiency (typically days 30-100 post-transplant), with risk of CMV disease (pneumonia, GI disease, hepatitis, retinitis), managed with universal prophylaxis (letermovir) or PCR-guided preemptive therapy with ganciclovir/valganciclovir/foscarnet/cidofovir, and adoptive T-cell therapy for refractory cases.

Written by: Saygı Hospital Health Guide Editorial Board
Last updated:

This content has been compiled by the Saygı Hospital Health Guide Editorial Board and is periodically reviewed by a specialist physician.

References (5)

This content is for informational purposes only and does not constitute medical advice. You can book an appointment at our Internal Medicine department. Book Appointment →

What is CMV Reactivation After Hematopoietic Cell Transplantation (HCT)?

Cytomegalovirus (CMV) is a ubiquitous β-herpesvirus that establishes lifelong latency in hematopoietic precursors, monocytes, and endothelial cells. In hematopoietic cell transplantation (HCT), CMV reactivation occurs during prolonged T-cell immunodeficiency, with peak risk between days 30-100 post-transplant. Reactivation rates are 30-70% in CMV-seropositive recipients of allogeneic HCT, with higher rates in T-cell depleted, mismatched unrelated donor, or umbilical cord blood transplants. CMV disease (end-organ involvement) develops in 5-30% without preemptive therapy, with mortality of CMV pneumonia historically 60-80%.

Risk stratification for CMV reactivation includes donor/recipient serostatus (highest risk D-/R+ where recipient lacks CMV-specific T-cells from donor), T-cell depletion (anti-thymocyte globulin, alemtuzumab), CD34+ selection, mismatched/unrelated/cord blood donors, acute and chronic GVHD requiring corticosteroids >1 mg/kg/day, and tissue source (cord blood highest). Late CMV reactivation (>day 100) occurs in 17% with chronic GVHD or impaired CMV-specific immunity.

Management strategies include: 1) Universal prophylaxis with letermovir 480 mg PO daily from days 0-100 (Marty et al. NEJM 2017, reduces clinically significant CMV by 60%, improves overall survival); 2) PCR-guided preemptive therapy with weekly CMV viral load monitoring, treating with ganciclovir 5 mg/kg BID IV or valganciclovir 900 mg BID PO when threshold (institution-specific 200-1000 IU/mL) reached; 3) Targeted therapy for established CMV disease with full-dose ganciclovir/foscarnet plus adjunctive IVIG for pneumonia; 4) Foscarnet for marrow-suppressive ganciclovir failures; 5) Cidofovir or maribavir for ganciclovir-resistant strains; 6) Adoptive CMV-specific T-cell therapy for refractory disease.

Symptoms

Asymptomatic viremia detected on PCR surveillance
Fever of unknown origin
Cytopenias (especially neutropenia)
Pneumonia: dyspnea, hypoxia, cough, infiltrates
GI disease: dysphagia, abdominal pain, diarrhea, GI bleeding
Hepatitis: elevated transaminases
Retinitis: floaters, blurred vision, scotomas (rare in HCT)

Risk Factors

CMV donor-/recipient+ mismatch (highest risk)
Acute or chronic GVHD requiring high-dose corticosteroids
T-cell depletion (ATG, alemtuzumab, CD34+ selection)
Mismatched unrelated donor (MMUD), haploidentical, cord blood
Late post-transplant impaired CMV-specific T-cell immunity
Active GVHD requiring intensified immunosuppression
Lymphopenia and prolonged immune reconstitution

When to See a Doctor?

If you experience any of the following symptoms, seek medical attention promptly:

  • Routine CMV PCR surveillance per institution protocol
  • Rising CMV viral load on weekly PCR (preemptive therapy)
  • Fever, cytopenias, or unexplained organ dysfunction post-HCT
  • Respiratory symptoms (CMV pneumonia workup with BAL)
  • GI symptoms (endoscopy with biopsy for CMV inclusions)
  • Refractory CMV viremia despite ganciclovir (resistance testing)
  • Visual symptoms (ophthalmologic evaluation for CMV retinitis)

Treatment Methods

01
Letermovir 480 mg PO daily for prophylaxis (days 0-100, FDA-approved)
02
Preemptive: ganciclovir 5 mg/kg IV BID or valganciclovir 900 mg PO BID
03
Maintenance after PCR negative: ganciclovir 5 mg/kg/day or valganciclovir 900 mg/day
04
CMV pneumonia: ganciclovir + IVIG (500 mg/kg every other day)
05
Foscarnet 60 mg/kg IV q8h (marrow toxicity, ganciclovir resistance)
06
Cidofovir or maribavir for ganciclovir-resistant CMV
07
Adoptive transfer of CMV-specific cytotoxic T-lymphocytes (CTL)

Which Department to Visit?

You can visit our Enfeksiyon Hastalıkları department for these complaints. Our specialist physicians will create the most suitable treatment plan for you.

Learn About Enfeksiyon Hastalıkları Department

Let us help you

You can make an appointment with our specialists or contact us for your concerns.

Book AppointmentContact Us

Related Health Topics

Other articles from the same department you may want to explore.

Flu (Influenza)

Enfeksiyon Hastalıkları

Influenza is a seasonal contagious respiratory disease caused by influenza viruses; it presents with high fever, muscle pain, and severe fatigue.

COVID-19

Enfeksiyon Hastalıkları

COVID-19 is a contagious disease caused by the SARS-CoV-2 coronavirus with a wide clinical spectrum ranging from asymptomatic to severe pneumonia.

Upper Respiratory Tract Infection

Enfeksiyon Hastalıkları

Upper respiratory tract infections are diseases that include common cold, pharyngitis, sinusitis, and laryngitis, often of viral origin and self-limited.

Urinary Tract Infection

Enfeksiyon Hastalıkları

Urinary tract infections are common bacterial infections most often caused by Escherichia coli, presenting with burning and frequent urination.

Hepatitis A (HAV)

Enfeksiyon Hastalıkları

Hepatitis A is an acute, self-limited liver infection transmitted via the fecal-oral route causing acute hepatitis without chronicity; supportive care suffices in most cases, while vaccination prevents outbreaks and post-exposure prophylaxis within 2 weeks is effective.

Hepatitis B

Enfeksiyon Hastalıkları

Hepatitis B is a contagious infection caused by HBV virus transmitted via blood, sexual intercourse, and mother-to-child, that can become chronic and progress to cirrhosis and liver cancer.

Hepatitis C

Enfeksiyon Hastalıkları

Hepatitis C is a liver disease caused by HCV virus transmitted mainly by blood; the rate of chronicity is high, but cure is possible with new antiviral drugs.

HIV/AIDS Information

Enfeksiyon Hastalıkları

HIV is a virus that targets the immune system; if untreated, it progresses to AIDS. With modern antiretroviral therapy, HIV-positive individuals can lead healthy, long lives.

Health Disclaimer: The information on this page is prepared for general informational purposes only. It does not replace medical diagnosis and treatment. Please consult your physician for your complaints. Saygı Hospital does not accept responsibility for actions taken based on the information on this page.